Pharmacovigilance and ICSR Reporting: A Guide for Clinical Trial Sponsors
Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects of medicines. For clinical trial sponsors, robust PV processes are a regulatory requirement and a patient safety imperative.
What Is Pharmacovigilance in Clinical Trials?
Clinical trial pharmacovigilance encompasses the collection, management, and reporting of adverse events (AEs) and serious adverse events (SAEs) during a clinical trial. It includes individual case safety report (ICSR) processing, expedited reporting to regulatory authorities, aggregate safety reporting, and signal detection. PV responsibilities are typically shared between the sponsor and the CRO, and must be clearly defined in a pharmacovigilance agreement.
Individual Case Safety Reports (ICSRs)
An ICSR is a report of an adverse event in a single patient. ICSRs are the primary unit of pharmacovigilance data. For clinical trials, SAEs must be reported to the sponsor within 24 hours of the investigator becoming aware of them. The sponsor then assesses causality, seriousness, and expectedness, and determines whether expedited reporting to regulatory authorities is required. ICSRs are coded using MedDRA and submitted to regulatory agencies in E2B(R3) format.
Expedited Reporting: SUSARs
A Suspected Unexpected Serious Adverse Reaction (SUSAR) is a serious adverse reaction that is both unexpected (not listed in the investigator brochure) and considered possibly related to the investigational medicinal product. SUSARs must be reported to regulatory authorities within 7 days (fatal or life-threatening) or 15 days (all other SUSARs). Expedited reporting timelines are strictly enforced; failure to report within the required timeframe is a common inspection finding.
MedDRA Coding
MedDRA (Medical Dictionary for Regulatory Activities) is the international medical terminology used to code adverse events, medical history, and indications in clinical trial and post-marketing safety data. Accurate MedDRA coding is critical for safety signal detection and aggregate reporting. Coding should be performed by a qualified medical coder using the current MedDRA version, and coding conventions should be defined in the PV plan before coding begins.
Aggregate Safety Reports
Aggregate safety reports summarise the safety profile of an investigational or marketed medicine over a defined period. Key aggregate reports include the Development Safety Update Report (DSUR) for clinical trials, the Periodic Safety Update Report (PSUR) for marketed products, and the Periodic Benefit-Risk Evaluation Report (PBRER). These reports are submitted to regulatory authorities on a defined schedule and require a comprehensive analysis of all available safety data.
Signal Detection and Risk Management
Signal detection involves the systematic analysis of safety data to identify new or changing safety concerns. In clinical trials, signal detection is typically performed by the Data Safety Monitoring Board (DSMB) or the sponsor's safety team. Statistical methods such as disproportionality analysis are used in post-marketing surveillance. Identified signals must be assessed, documented, and, where appropriate, reflected in updates to the investigator brochure, risk management plan, or product labelling.
Key Checklist
Frequently Asked Questions
What is an ICSR in pharmacovigilance?
An Individual Case Safety Report (ICSR) is a report of an adverse event in a single patient. ICSRs are the primary unit of pharmacovigilance data. They are coded using MedDRA and submitted to regulatory authorities in E2B(R3) format. In clinical trials, SAEs must be reported to the sponsor within 24 hours of the investigator becoming aware of them.
What is a SUSAR and when must it be reported?
A SUSAR (Suspected Unexpected Serious Adverse Reaction) is a serious adverse reaction that is both unexpected (not listed in the investigator brochure) and considered possibly related to the investigational product. SUSARs must be reported to regulatory authorities within 7 days if fatal or life-threatening, or within 15 days for all other SUSARs.
What is MedDRA and why is it used in pharmacovigilance?
MedDRA (Medical Dictionary for Regulatory Activities) is the international medical terminology used to code adverse events, medical history, and indications in clinical trial and post-marketing safety data. It is required by regulatory authorities worldwide and enables consistent safety data analysis and comparison across studies and products.
What is a DSUR in clinical trials?
A Development Safety Update Report (DSUR) is an annual aggregate safety report submitted to regulatory authorities during clinical development. It summarises all safety data collected during the reporting period, including ICSRs, aggregate analyses, and any new safety findings. DSURs are required by the FDA, EMA, and other regulatory agencies.
How does a CRO support pharmacovigilance in clinical trials?
A specialist CRO provides pharmacovigilance services including ICSR processing, MedDRA coding, expedited reporting, SAE reconciliation, aggregate report preparation (DSUR, PSUR, PBRER), and signal detection support. PV responsibilities are defined in a pharmacovigilance agreement between the sponsor and the CRO.
Need specialist support?
IDDCR Global Research provides specialist CRO services for pharmaceutical, biotechnology, and medical device sponsors. Contact us to discuss your requirements.